Natco Pharma

Natco Pharma proposed a rights issue of up to ₹1,300 crore, while leaving the issue price, entitlement ratio and timetable unspecified. It earmarked ₹810.5 crore to repay borrowings and ₹110 crore for research and development, with the residual proceeds intended for unidentified acquisitions, strategic initiatives and general corporate purposes. Natco held a 49% stake in South Africa’s Adcock Ingram and operated nine manufacturing facilities and two research centres. Consolidated total income was ₹4,375.9 crore in the year ended March 2026, including ₹3,234.5 crore from export formulations.

Powered by Tijori

Natco Pharma's board approved a rights issue of fully paid equity shares to eligible shareholders to raise up to ₹1,300 crore, subject to regulatory approvals. The issue price, rights entitlement ratio and record date were left for later finalisation, while a fund-raising committee and draft letter of offer were approved. The proposed issue would require changes to the planned demerger of Natco Crop Health Sciences; the scheme had received observation letters from both stock exchanges but had not yet been filed with the National Company Law Tribunal. Natco had earlier been evaluating a fund raise of up to ₹2,000 crore. Consolidated revenue was ₹4,375.9 crore in FY26, while net cash stood at about ₹1,400 crore after spending on its Adcock Ingram investment.

Powered by Tijori

Sept 9 (Reuters) - Natco Pharma Ltd NATP.NS:

• APPROVES RIGHTS ISSUE OF EQUITY SHARES UP TO 13 BILLION RUPEES

Further company coverage: NATP.NS

(([email protected];))

Aug 25 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - INVESTING $14 MILLION IN EGENESIS, INC VIA UNITS

Source text: [ID:]

Further company coverage: NATP.NS

(([email protected];;))

Natco Pharma's board approved exploring a fund raise of up to ₹2,000 crore through equity shares or other securities, subject to shareholder and regulatory approvals. The proposal did not specify an instrument, pricing or use of proceeds. The company reported consolidated revenue of ₹794.4 crore and profit after tax of ₹206.5 crore for the quarter ended June 30, 2026, down from ₹1,390.6 crore and ₹480.3 crore respectively a year earlier. It attributed the decline mainly to lower lenalidomide revenue, partly offset by growth in its base business. The board declared an interim dividend of ₹1.50 per share. Natco's consolidated results included ₹84.3 crore of profit from its Adcock Ingram associate, whose revenue was ₹1,582.8 crore in the quarter. The group had about ₹2,400 crore of net cash and had recently increased its holding in Adcock Ingram to 49%.

Powered by Tijori

Aug 14 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - DECLARES Q1 FY27 INTERIM DIVIDEND OF 1.50 RUPEE PER EQUITY SHARE

• NATCO PHARMA - APPROVED FUND RAISING UP TO 20 BILLION RUPEES

Source text: ID:nBSE8C1768

Further company coverage: NATP.NS

(([email protected];))

Aug 11 (Reuters) - Natco Pharma Ltd NATP.NS:

• BOARD TO MEET ON AUGUST 14, 2026 TO CONSIDER FUND RAISING

• TO CONSIDER FUND RAISING VIA EQUITY OR OTHER SECURITIES

Source text: ID:nBSELkP58

Further company coverage: NATP.NS

(([email protected];))

** Drug maker Natco Pharma's shares NATP.NS rise as much as 4.5%, their sharpest intraday rise in two weeks, to 987.55 rupees apiece

** NATP last up 2.6%

** Rise after NATP receives tentative approval from the U.S. drug regulator for Olaparib, 100 mg and 150 mg, a bioequivalent to the reference listed drug (RLD) Lynparza tablets

** Olaparib, which is used to treat specific types of cancers, had estimated sales of $1.4 billion in the U.S for 12 months ending March 2026, NATP says in an exchange filing

** NATP shares are up 7.7% in 2026 so far, lagging the 15% rise in the pharma index .NIPHARM, exchange data shows

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Natco Pharma received tentative approval from the US Food and Drug Administration on July 18, 2026, for its generic version of AstraZeneca’s cancer drug Lynparza (olaparib) in 100 mg and 150 mg doses. Natco will manufacture the tablets, and its partner Alembic Pharmaceuticals will distribute the product in the US market. The brand drug had estimated US sales of approximately $1.4 billion for the twelve months ended March 2026, according to industry data. The approval is tentative because Paragraph IV patent litigation is ongoing, meaning Natco cannot launch the product until the legal process concludes or the patents expire. The FDA’s tentative nod confirms that the generic meets all quality, safety and efficacy standards, positioning Natco for a potential commercial launch if it prevails in court.

Powered by Tijori

Natco Pharma’s board on July 8, 2026, approved two major capital commitments in South Africa. The company will invest up to ₹1,400 crore in its wholly owned subsidiary, Natco Pharma South Africa Proprietary Limited, and, in a separate transaction, will acquire an additional 13.25 per cent stake in Adcock Ingram Holdings Proprietary Limited for about 1.8 billion South African rand (₹1,069 crore), taking its total holding to 49 per cent. Adcock Ingram, one of South Africa’s largest pharmaceutical companies with a leading over-the-counter portfolio, reported a topline of approximately $423 million for the nine months ended March 2026. The board approvals are subject to customary closing conditions and regulatory clearances in India and South Africa, with completion targeted before the end of July 2026.

Powered by Tijori

July 8 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - APPROVES INVESTMENT UP TO 14 BILLION RUPEES IN WHOLLY OWNED SUBSIDIARY IN SOUTH AFRICA

• NATCO PHARMA - BOARD APPROVES INCREASING STAKE IN ADCOCK INGRAM HOLDINGS TO 49%

Source text: ID:nBSE5hXgBn

Further company coverage: NATP.NS

(([email protected];))

May 29 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA MARCH-QUARTER CONSOL NET PROFIT 2.68 BILLION RUPEES

• NATCO PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 7.39 BILLION RUPEES

Source text: ID:nBSE8vJ6vT

Further company coverage: NATP.NS

(([email protected];))

May 15 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - GETS DEMAND OF 49.2 MILLION RUPEES FROM NATIONAL PHARMACEUTICAL PRICING AUTHORITY

Source text: ID:nBSE9tfp56

Further company coverage: NATP.NS

(([email protected];))

March 24 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - TO INCORPORATE WHOLLY OWNED SUBSIDIARY IN NIGERIA WITH INVESTMENT UP TO $100,000

• NATCO PHARMA - TO LIQUIDATE WHOLLY OWNED SUBSIDIARY IN AUSTRALIA

• NATCO PHARMA - BOARD APPROVES SCHEME OF ARRANGEMENT WITH NATCO CROP HEALTH SCIENCES

• NATCO PHARMA - CROP HEALTH SCIENCES TO ISSUE 1:1 SHARES TO NATCO PHARMA SHAREHOLDERS

Source text: ID:nNSE41gmTn

Further company coverage: NATP.NS

(([email protected];))

** Analysts highlight strong semaglutide opportunity as ~10 Indian firms roll out generics

** Novo Nordisk's semaglutide patent expires this week

** Nomura says Zydus Lifesciences ZYDU.NS, Alkem Laboratories ALKE.NS, Sun Pharmaceutical Industries SUN.NS among most differentiated launches

** Adds Zydus's adjustable-dose reusable pen key differentiator

** Note Alkem "aggressive on pricing", with disposable pens at 2,000 rupees/month vs peers at 4,200-5,200 rupees

** Sees India's semaglutide market exceeding 120 bln rupees ($1.28 bln) in five years; India's obesity drug market at ~15 bln rupees as of March, per Pharmarack estimates

** Macquarie says Torrent Pharmaceuticals TORP.NS gains first-mover advantage in oral semaglutide

** Flags steep discounts of 50%-80% on pens, up to 85% on vials from Eris Lifesciences ERIS.NS, Glenmark Pharmaceuticals GLEN.NS, Natco Pharma NATP.NS

** Sees near-term price erosion before volume-driven expansion

($1 = 93.9125 Indian rupees)

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

March 20 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - LAUNCHES SEMAGLUTIDE GENERIC INJECTION MULTI DOSE VIALS IN INDIA

• NATCO PHARMA - MULTI DOSE VIALS LAUNCHED AT 1,290 RUPEES AND 1,750 RUPEES PER MONTH

• NATCO PHARMA - PEN DEVICE PRICED AT 4,000 RUPEES AND 4500 RUPEES PER MONTH, LAUNCH EXPECTED APRIL 2026

Source text: ID:nNSE2S1pW8

Further company coverage: NATP.NS

(([email protected];))

March 18 (Reuters) - Natco Pharma Ltd NATP.NS:

• BOARD TO CONSIDER DEMERGER OF AGROCHEMICALS DIVISION

Source text: ID:nBSEtvJ4y

Further company coverage: NATP.NS

(([email protected];))

March 3 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - LAUNCHES POMALIDOMIDE CAPSULES IN U.S. MARKET

Source text: ID:nNSEHZsrg

Further company coverage: NATP.NS

(([email protected];))

March 3 (Reuters) - Breckenridge Pharmaceutical:

• BRECKENRIDGE PHARMACEUTICAL- BRECKENRIDGE LAUNCHES POMALIDOMIDE CAPSULES

• BRECKENRIDGE PHARMACEUTICAL-POMALIDOMIDE CAPSULES AVAILABLE ONLY THROUGH PS-POMALIDOMIDE REMS PROGRAM

Source text: ID:nPn4Q6sTZa

(([email protected];))

Feb 25 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - COMPANY TO LAUNCH SEMAGLUTIDE IN INDIA IN MARCH 2026

Source text: ID:nBSE4rCg7D

Further company coverage: NATP.NS

(([email protected];))

Feb 24 (Reuters) - Eris Lifesciences Ltd ERIS.NS:

• ANNOUNCES STRATEGIC PARTNERSHIP WITH NATCO PHARMA FOR SEMAGLUTIDE LAUNCH IN INDIA

Further company coverage: ERIS.NS

(([email protected];;))

** Natco Pharma NATP.NS jumps ~11% to 913 rupees

** Pharma co gets Indian drug regulator's approval to manufacture and market generic semaglutide injection in country; injection used to treat type-2 diabetes mellitus, manage weight

** Product launch likely in March

** Trading volume at more than 8x the 30-day average

** YTD, NATP up ~1% vs ~2% fall in Nifty 500 index .NIFTY500

(Reporting by Vijay Malkar)

(([email protected];))

Feb 13 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - API UNIT IN CHENNAI RECEIVES ESTABLISHMENT INSPECTION REPORT FROM U.S. FDA

• NATCO PHARMA - API UNIT IN CHENNAI RECEIVES EIR FROM U.S. FDA

• NATCO PHARMA - COMPANY RECEIVED SEVEN OBSERVATIONS

• NATCO PHARMA - RECEIVED EIR CLASSIFIED AS VOLUNTARY ACTION INDICATED

Source text: ID:nBSEM8T3j

Further company coverage: NATP.NS

(([email protected];))

Feb 12 (Reuters) - Natco Pharma Ltd NATP.NS:

• DEC-QUARTER CONSOL NET PROFIT 1.52 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 6.47 BILLION RUPEES

• RE-APPOINTMENT OF RAJEEV NANNAPANENI AS CEO

• DECLARED DIVIDEND OF RS. 1.50 RUPEES PER SHARE

• RE-APPOINTMENT OF VENKAIAH CHOWDARY NANNAPANENI AS CHAIRMAN & MANAGING DIRECTOR

Further company coverage: NATP.NS

(([email protected];))

Feb 3 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - RECEIVES TENTATIVE APPROVAL FOR ERDAFITINIB TABLETS

Source text: ID:nBSE19q71R

Further company coverage: NATP.NS

(([email protected];;))

Jan 30 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - NATCO PHARMA ASIA BUYS 49% OF PT NATCO LOTUS FARMA FROM PT LOTUS FARMA INDONESIA

• NATCO PHARMA - COST OF ACQUISITION IS ABOUT 77 MILLION RUPEES

Source text: ID:nNSEW2yQ3

Further company coverage: NATP.NS

(([email protected];))

** Natco Pharma NATP.NS rises 3.3% to 840 rupees

** Delhi Court dismisses appeal filed against co by F. Hoffmann-La Roche AG over launch of Risdiplam drug in India

** Judgment paves way for co to launch generic version of drug 'Risdiplam', used to treat spinal muscular atrophy

** Co to launch product with immediate effect at 15,900 rupees; offer some discount to certain deserving patients through its patient access programme

** Around 2.2 mln shares traded, more than 5x the 30-day avg

** YTD, NATP falls ~39%

(Reporting by Vijay Malkar)

(([email protected];))

Rewrites, updates shares, adds analysts' comments

By Ananta Agarwal and Rishika Sadam

Sept 26 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 2% on Friday after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented drugs, effective Oct. 1.

The U.S. is India's largest market for pharmaceutical exports, accounting for over a third of the total volume, mostly of cheaper generic drugs.

Of the 20 index constituents, 18 traded in the red as of 2:37 p.m. IST.

Analysts described the decline as "sentimental", noting that India's exports to the U.S. are primarily generic medicines, which may not be affected by the tariffs.

Sun Pharmaceutical Industries SUN.NS, India's largest drugmaker by revenue and the heaviest stock on the index, fell about 3%. Sun Pharma markets patented drugs, including Ilumya, a psoriasis treatment approved by the U.S. FDA.

The company also has a contract manufacturing unit through EU partners for specialty drugs, where a 15% tariff applies to EU exports to the U.S., according to Vishal Manchanda, equity analyst at Systematix Group.

"The impact on Sun is not very meaningful," he said. "It may be between 1% to 3% of EBITDA."

Laurus Labs LAUL.NS declined the most among constituents of the index, down about 6%.

"There is a general worry that CDMO (contract drug manufacturing organisations) might be impacted as the U.S. moves manufacturing in-house," Manchanda added.

Biocon, which makes complex biosimilars for cancer treatment and has significant U.S. exposure, is down about 4.6%.

"Uncertainty remains whether complex generics and biosimilars will face future tariffs," ICICI Securities analyst Pankaj Pandey said in a note on Friday.

(Reporting by Ananta Agarwal in Bengaluru; Editing by Nivedita Bhattacharjee and Janane Venkatraman)

(([email protected];))

Sept 18 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA LTD - FDA CONDUCTED INSPECTION AT NATCO PHARMA IN KOTHUR, HYDERABAD

• NATCO PHARMA LTD - RECEIVES EIR CLASSIFYING FACILITY AS 'VAI'

Source text: ID:nBSE8nbfJZ

Further company coverage: NATP.NS

(([email protected];))

** Shares of Natco Pharma NATP.NS down 0.7% at 903 rupees, while Nifty Pharma index up 1.2%

** Earlier was at 871 rupees, its lowest level since June 27

** Co reported 28.1% y/y fall in Q1 consol net profit as expenses rose

** Co says business faced pricing pressure in U.S. product portfolio, incurred increased R&D expenses on account of high value projects

** Average rating by 8 analysts is "hold"; median PT is 1,040.5 rupees - data compiled by LSEG

** YTD, NATP down 35.1% vs 6.7% fall in Nifty Pharma index

($1 = 87.6138 Indian rupees)

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))